.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,299,118

« Back to Dashboard

Claims for Patent: 8,299,118

Title:Enhanced bimatoprost ophthalmic solution
Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/370,529
Patent Claims: 1. A method of lowering intraocular pressure in a person with glaucoma or ocular hypertension, the method comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the method lowers intraocular pressure and results in less hyperemia as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

2. The method of claim 1 wherein the first composition has a pH of about 7.3.

3. The method of claim 1 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.

4. The method of claim 1 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA.

5. The method of claim 1 wherein the method is effective in treating glaucoma.

6. The method of claim 1 wherein the method is effective in treating ocular hypertension.

7. A method of lowering intraocular pressure in a person with glaucoma or ocular hypertension, the method comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the method lowers intraocular pressure without a substantial reduction in the intraocular pressure lowering benefit provided by the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

8. The method of claim 7 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition.

9. The method of claim 7 wherein the first composition has a pH of about 7.3.

10. The method of claim 7 wherein the first composition is a solution.

11. The method of claim 7 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.

12. The method of claim 7 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA.

13. The method of claim 7 wherein the method is effective in treating glaucoma.

14. The method of claim 7 wherein the method is effective in treating ocular hypertension.

15. A method of reducing the amount of bimatoprost administered to a person in a treatment for glaucoma or ocular hypertension, comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the composition remains useful in treating glaucoma or ocular hypertension despite a lower concentration of bimatoprost as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

16. The method of claim 15 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition.

17. The method of claim 15 wherein the first composition has a pH of about 7.3.

18. The method of claim 15 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.

19. The method of claim 15 wherein the first composition is applied topically.

20. The method of claim 15 wherein the method is effective in treating glaucoma.

21. The method of claim 20 wherein the glaucoma is open-angle glaucoma.

22. The method of claim 15 wherein the method is effective in treating ocular hypertension.

23. A method of reducing the amount of bimatoprost administered to a person in a treatment for glaucoma or ocular hypertension, comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the benzalkonium chloride concentration of the first composition increases the permeability of bimatoprost across corneal epithelial cell layers as compared to once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

24. The method of claim 23 wherein the first composition remains useful in treating glaucoma or ocular hypertension despite a lower concentration of bimatoprost as compared to the second composition.

25. The method of claim 23 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition.

26. The method of claim 23 wherein the method is effective in treating glaucoma.

27. The method of claim 23 wherein the method is effective in treating ocular hypertension.

28. The method of claim 23 wherein the first composition has a pH of about 7.3.

29. The method of claim 23 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA.

30. The method of claim 23 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc